

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Pharmacologic Interventions for Preventing Chondrocyte Apoptosis in Rheumatoid Arthritis and Osteoarthritis

Charles J. Malesmud

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.73174>

Abstract

Chronic inflammation drives the progression of rheumatoid arthritis (RA) and osteoarthritis (OA) to synovial joint failure. The inflammatory state in both musculoskeletal diseases is associated with significantly elevated levels of pro-inflammatory cytokines in joint synovial fluid, which is best exemplified by increases in interleukin-1 β (IL-1 β), IL-6, IL-17, tumor necrosis factor- α , among others, as well as increased activity of soluble mediators such as nitric oxide and certain growth factors including vascular endothelial growth factor and fibroblast growth factor. The multitude of these factors activate chondrocyte signal transduction pathways resulting in programmed cell death, otherwise known as apoptosis as well as compromising chondrocyte autophagy. Importantly, chondrocyte apoptosis causes a loss of articular cartilage vitality which dampens cartilage repair mechanisms because at present, the possibility that chondrocyte progenitor cells could replace those differentiated chondrocytes lost via apoptosis remains debatable. Certain pharmacologic interventions which have been proven to induce apoptosis in various cancer cell studies *in vitro* suggest the possibility that drugs could be developed to specifically suppress or completely inhibit chondrocyte apoptosis in RA and OA cartilage. This review supports that contention and indicates that apoptosis can be inhibited by identifying novel cellular targets which promote apoptosis and autophagy.

Keywords: apoptosis, chondrocyte, osteoarthritis, rheumatoid arthritis, signal transduction

1. Introduction

Controlled cell death otherwise known as programmed cell death or apoptosis constitutes a critical event which is germane to the normal development of the immune system, the appropriate

integration of cells within tissues and organs and organ homeostasis [1–7]. However, the aberrant frequency of apoptotic cells can compromise normal tissue architecture and, in doing so, contribute to the loss of cell vitality [8–10]. This is especially the case in explaining the loss of chondrocyte viability in arthritic conditions of synovial joints, such as rheumatoid arthritis (RA) and osteoarthritis (OA).

Significant progress has been achieved over the previous decade or so in furthering our understanding of the cellular and molecular events that trigger the increased frequency of chondrocyte apoptosis in RA and OA [11–16]. These advances include (1) an appreciation that the significant increase in the levels of pro-inflammatory cytokines in synovial fluid from RA and OA patients also can induce chondrocyte apoptosis *in vitro* [17–21]; (2) that the elevated frequency of chondrocyte apoptosis by these cytokines is deregulated by altered signal transduction which can involve continuous activation of stress-activated/mitogen-activated protein kinases (SAPK/MAPK) [22–25], the Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway [26–31], the phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway [32–36], and other protein kinase pathways [37–40]; (3) that specific co-factors are capable of regulating the activation of these signaling pathways [41–44]; and (4) that micro-RNAs (mi-RNAs) can regulate the activity of these co-factors and, in this manner, control the induction of apoptosis via these signaling pathways [45–48].

Furthermore, the increased frequency of chondrocyte apoptosis now confirmed in guinea pig OA cartilage [49] as well as human RA and OA articular cartilage [50–53] presents a particularly onerous scenario for the survival of synovial joints under these conditions. Although a population of chondroprogenitor cells was identified in several studies of adult normal and diseased articular cartilage [54–56], significant repair of damaged articular cartilage in RA and OA by these cells is effete. This effect on cartilage repair may result from elevated levels of pro-inflammatory cytokines such as IL-17, which was recently shown to inhibit the chondrocyte maturation lineage emanating from progenitor cells in RA [57]. Therefore, even if chondrocyte precursor cells exist in adult articular cartilage which could potentially become authentic chondrocytes lost from articular cartilage via apoptosis or chondrocytes lost via diffusion of cartilage extracellular matrix fragments into synovial fluid, the reduction in chondrocyte vitality via apoptosis would be a challenging event to overcome, especially in a synovial joint microenvironment replete with pro-inflammatory cytokines.

In this chapter, we have systematically examined the mechanistic underpinning for identifying novel targets in order to suppress or even inhibit chondrocyte apoptosis in RA and OA. However, the scenario in RA, in particular, is even more complex than in OA because in the context of devising therapeutic strategies designed to inhibit chondrocyte apoptosis in RA, one must also take into account the fact that in the hyperplastic RA synovial tissue, comprised of activated synoviocytes, immune cells, macrophages and other inflammatory cells are generally considered to be relatively “apoptosis-resistant” [58, 59]. Thus, this characteristic of the RA joint ensures a plentiful source of immune-mediated cells and non-immune inflammatory cells which drive the progression of RA. It is also likely that at

some time during the course of the progression of OA, immune-mediated inflammation may also cause a similar chronic inflammatory microenvironment, as found in RA, to arise and persist in OA synovial tissue [55] resulting, in part, in an increased frequency of apoptotic chondrocytes [60].

2. Compelling evidence that many factors relevant to RA and OA promote or induce chondrocyte apoptosis *in vitro*

Analyses of synovial fluids and sera from RA and OA patients with active disease showed that these samples contained significantly elevated levels of various pro-inflammatory cytokines and growth factors when compared to a control group [52–68]. Of note, incubation of rat [69], non-arthritis or human chondrocytes from OA cartilage [70–76] or immortalized lines of human chondrocytes [77] with physiological levels of these cytokines, growth factors (e.g., VEGF and FGF) or additional soluble mediators (e.g., nitric oxide) were shown to induce apoptosis, which was accompanied by activation of SAPK/MAPK, JAK/STAT or PI3K/Akt/mTor signaling in these cells [78–81]. In addition, mediators of inflammation, including prostaglandin E₂ and neuropeptides (e.g., Substance P), are also implicated in perpetuating chronic inflammation [38]. The induction of apoptosis was also shown to be related to altered levels of various down-regulators of apoptosis. These included BCL-2-like protein-11 (Bim) [18], B-cell lymphoma-2 (Bcl-2) [75], cell-derived inhibitors of apoptosis proteins (IAPs) [81–84] and Suppressor of Cytokine Synthesis (SOCS) [85, 86]. Furthermore, alterations in the functions of mitochondria [87] and endoplasmic reticulum (ER) [88–91] related to cell stress, the generation of reactive oxygen species [92] and the recently described advanced oxidation protein products [93] with respect to their capacity to induce apoptosis were reported as well. Taken together, these results provided compelling evidence that pro-inflammatory cytokines, growth factors and soluble mediators germane to the progression of RA and OA are responsible for inducing chondrocyte apoptosis in these conditions.

3. The relationship between apoptosis and autophagy

A recent review of RA pathogenesis by Angelotti et al. [94] emphasized the view that numerous cells comprising the innate immune system, including macrophages, dendritic cells, mast cells, natural killer cells and neutrophils as well as T-cells and B-cells, regulators of adaptive immunity, are primarily responsible for perpetuating the state of chronic inflammation through their capacity to alter the survival of resident synovial fibroblasts. It is also likely that such cell combinations are also involved in the progression of OA as well, as evidenced by the skewing of cartilage homeostasis toward catabolism, and the loss of chondrocyte vitality via the induction of apoptosis [95–97]. However, it was previously shown that the classical apoptosis cascade can be activated by various pro-inflammatory cytokines, and certain growth factors, chemokines, chemokine receptors (**Table 1**) and other interleukins, including

IL-8 (CXCL8) and adhesion molecules [64]. Thus, these factors are likely to be the most influential in inducing apoptosis pathway RA. However, a non-classical form of apoptosis, termed, “chondroptosis” is just as likely to be activated in OA. In that regard, “chondroptosis” involves an increase in the number of ER and Golgi apparatus reflecting an increase in protein synthesis that accompanies the loss of viable chondrocytes [98].

Furthermore, changes in the number of viable articular chondrocytes in experimentally induced arthritis [99], human RA [100], and OA are almost certainly associated with the autophagic-mediated cell death of chondrocytes [101–105], which occurs in concert with the activation of the extrinsic apoptosis pathway, the latter mediated by Tumor necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL), Death Receptor-5 (DR5) and caspase-3 [106, 107]. In that regard, it was noteworthy that Huang et al. [108] reported that exogenous leptin promoted chondrocyte apoptosis while inhibiting chondrocyte autophagy via the up-regulation of lysyl oxidase-like 3 (LOXL3). Thus, in their study [108], overexpression of LOXL3 inhibited chondrocyte autophagy by activating mechanistic target of rapamycin complex-1 (mTORC1) [36]. In contrast, cartilage-specific

Cytokine, chemokine, chemokine receptors and growth factors	Reference
IL-17, IL-18BP	[62]
IL-17, IL-20, IL-21	[63]
IL-7	[64]
IL-12/IL-23	[64]
IL-15/IL-16	[64]
IL-17/IL-18	[64]
IL-19/-20/-21	[64]
IL-32	[64]
VEGF ¹ ; TGF-β ₁ ² ; Leptin; FGF ³	[64–66]
CXCR3; CXCR4,-5; CXCR-1,-5,-6; IL-8; MIP-1α ⁴ ; GRO-α ⁵ (CXCL1); GRO-βγ ⁶ ; MCP-1 ⁷ ; RANTES ⁸ ; Eotaxin-1	[65, 68]
IL-6	[64, 67, 68]
TNF-α	[64, 67, 69]
IL-1β	[64]

¹Vascular endothelial growth factor.
²Transforming growth factor-β₁.
³Fibroblast growth factor.
⁴Macrophage inflammatory protein-1 (CCL3).
⁵Growth-related oncogene-α.
⁶GRO-βγ.
⁷Monocyte chemotactic protein-1.
⁸Regulated on activation, normal T-cell expressed and secreted.

Table 1. Cytokines, chemokines, chemokine receptors and growth factors in RA and OA.

deletion of mTOR resulted in the up-regulation of autophagy [102]. Autophagy protected mouse cartilage from degeneration [109]. Autophagy was also shown to protect chondrocytes from glucocorticoid-induced apoptosis via reactive oxygen species, Akt and FOXO3 signaling [110] as well as from advanced glycation end-product-induced apoptosis which was accompanied by lower levels of MMP-3 and MMP-13 in rat chondrocyte cultures [111].

4. Do micro-RNAs play a critical role in chondrocyte apoptosis?

Micro-RNAs (miRs) are critical mediators of mRNA degradation as well acting as repressors of translation. MiRs have been implicated in the development of skeletal long bones via their multiple effects on osteogenesis [112]. However, recent evidence has also improved the recognized role of miRs in RA pathology as a result of evidence that many miRs including miR-16, miR-146a/b, miR-150, miR-155 and miR-223 are over-expressed both in the peripheral circulation of RA patients and in the RA synovial joint [113], although other miRs relevant to RA, such as miR-21, miR-125a, miR-223, and miR-451 are principally found to be at elevated levels in the plasma and sera of RA patients.

Additional evidence has been presented to show that several of these miRs also regulate apoptosis. For example, the level of the pro-apoptotic protein, Bim, was increased when activated T-cells were incubated with a repressor of miR-148a resulting in an increase in the Th1 apoptotic response [114]. Thus, accumulating evidence showed that both the immune cells and chondrocyte apoptotic and autophagic response can be manipulated by either experimental overexpression or repression of various miRs which are relevant to OA [115] and RA [116] pathophysiology.

The results of numerous studies have confirmed the role of specific miRs as directly affecting apoptosis or indirectly affecting apoptosis through their activity on other molecules that regulate chondrocyte apoptosis. For example, miR-146a was reported to be over-expressed in OA [117]. In that regard, miR-146a was shown to promote human OA chondrocyte proliferation and to inhibit apoptosis by targeting tumor necrosis factor receptor-associated factor 6 (TRAF6) via NF- κ B [118, 119]. By contrast, miR-146a was also shown to target IL-1 β , to induce VEGF production, and to promote rat chondrocyte apoptosis via Smad4 [120]. On the other hand, silencing of miR-34a inhibited rat chondrocyte apoptosis [121], whereas overexpression of miR-34a promoted apoptosis in normal human chondrocytes by targeting SIRT1/p53 signaling [122], although other evidences indicated that miR-34a was increased in intervertebral disc degeneration and was associated with an elevated frequency of apoptotic cartilage end plate chondrocytes [123]. In another study, glycerol-3-phosphate dehydrogenase 1-like protein was shown to be a target for miR-181a, which is deregulated in OA wherein human chondrocyte apoptosis was increased [124]. In yet another study, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) [36] was identified as the target for miR-181 whereby miR-181 up-regulated the expression of proteins associated with apoptosis, including caspase-3 and PARP. However, miR-181 also up-regulated MMP-2 (gelatinase A; 72 kDa gelatinase) and MMP-9 (gelatinase B; 92 kDa gelatinase) [125] which are two MMPs directly relevant to cartilage matrix protein degradation in arthritis [126].

Of note, several miRs were identified as potential targets for inducing chondrocyte survival and therefore could be considered anti-apoptosis factors; these included miR-98 [127–129], miR-9 [130], miR-15a-5p [131], miR-142-3p [132] and miR-502-5p [133]. Additional miRs, exemplified by miR-195 [134], miR-139 [135], miR-29b-3p [136], miR-488-3p [137] and miR-203 [138] could very well be included in this group. For example, by employing the C28/I2 line of immortalized human chondrocytes, Zhao et al. [138] showed that knockdown of miR-203 targeting the myeloid cell leukemia-1 (MCL-1) protein activated Wnt/ β -catenin and JAK/STAT signaling promoted chondrocyte survival.

To summarize this section, gaining a further understanding of how to manipulate specific miRs to achieve increased or decreased synthesis of specific targets known to influence chondrocyte apoptosis may signal the next major advance in targeted OA and RA therapy designed to promote chondrocyte survival.

5. Pharmacologic interventions designed to specifically inhibit chondrocyte apoptosis

5.1. Signal transduction pathways

Lewis and Malemud [82] previously reviewed several potential pharmacologic strategies designed to limit the loss of chondrocyte vitality via apoptosis. These included, targeting x-linked inhibitor of apoptosis (XIAP), tumor necrosis factor-like weak inducer of apoptosis (TWEAK), TRAIL, decoy-receptor-3 (Dcr3), tumor necrosis factor receptor protein-like molecules, p53 up-regulated modulator of apoptosis (PUMA), and apoptosis-signal-regulating kinases. In that regard, we proposed several interventional strategies which we acknowledged involved developing a deeper understanding of which signal transduction pathways were altered in RA and OA chondrocytes [19, 28, 36, 77, 82, 106]. For example, XIAP, an inhibitor of activated caspase-9, and caspases-3 and -7 [82] was also shown to interact with mitogen-activated protein kinase kinase 2 (MEKK2) [139]. The interaction between XIAP and MEKK2 resulted in a biphasic activation of NF- κ B, a known downstream effector of TNF- α -mediated apoptosis. This finding is relevant to the regulation of chondrocyte apoptosis in both RA and OA primarily because XIAP is a well-known inhibitor of apoptosis protein-3 (IAP3) [140]. In fact, we had previously shown that recombinant human TNF- α (rhTNF- α) induced human chondrocyte apoptosis via activation of p38, JNK1/2 and STAT3 [72], whereas apoptosis of the immortalized human chondrocyte line, C-28/I2 induced by rhTNF- α , but not by rhIL-6, was dependent on upstream MEK1/2 [77]. Therefore, we posit that in order to consider using potential drug interventions that alter the activation of various signaling pathways it will be useful to consider what we know about how alterations in receptor-mediated signaling pathways (reviewed in [19]) may influence apoptosis.

Activation of SAPK/MAPK signaling is most often associated with induction of chondrocyte apoptosis. Thus, induction of rabbit articular chondrocyte apoptosis by the nitric oxide (NO) donor sodium nitroprusside (SNP) was linked to inhibition of c-Jun-amino-terminal kinase (JNK) by virtue of the finding that the JNK small molecule inhibitor (SMI) SP600125, reduced

the frequency of apoptotic chondrocytes along with NO-induced NF- κ B, p53 and caspase-3 [141]. IL-1 β , another potent inducer of chondrocyte apoptosis, was also shown to be JNK-dependent as both chemical inhibitors of JNK as well as RNA interference with Bim, the latter up-regulated by IL-1 β , were shown to be phosphorylated-JNK-dependent [142]. In other studies, chondrocyte apoptosis was again linked to IL-1 β -induced activation of p38 kinase [143–145], along with JNK [145], and MMP-3 gene expression with IL-1 β negatively regulating chondrocyte autophagy [145]. Of note, AG490, a pan-JAK SMI significantly reduced leptin-induced chondrocyte apoptosis *in vitro* as well as reducing STAT3 phosphorylation, reactive oxygen species, MMP-13 and B-cell lymphoma 2-associated X protein [146]. Interestingly, Li et al. [147] showed that the PI3K/NF- κ B pathway was activated by TNF- α in human chondrocytes. However, the effect of leptin did not involve mTOR, suggesting that newly developed small molecule mTOR inhibitors (reviewed in [36]) might not be useful for neutralizing activated PI3K/NF- κ B in response to leptin-induced apoptosis.

Several attempts to employ various compounds and/or natural products to inhibit chondrocyte apoptosis have taken advantage of various findings related to the role of these compounds and natural products in many of the aforementioned signal transduction pathways. For example, IL-1 β -induced chondrocyte apoptosis was inhibited by oligomeric proanthocyanidin, a water-soluble plant polyphenolic compound [148]. Thus, the over-expression of peroxiredoxin 4 (PRDX4), a member of the PRDX family (a molecule essential for scavenging free radicals and reducing reactive oxygen species) reduced IL-1 β -induced rat chondrocyte apoptosis [149]. Importantly, AZD5363, an inhibitor of Akt activation also reduced the apoptosis protective effect of PRDX4. In another aspect, chondrocyte apoptosis induced by IL-1 β not only involved reduced Bcl-2 levels, activated (i.e., phosphorylated) Akt, and activated PRAS40, a proline-rich 40 kDa Akt substrate and an inhibitor of mTORC1 kinase activity, but was also linked to increasing the levels of Bax, and activated caspase-3/-9 [149].

Shikonin, a compound with anti-tumor, anti-inflammatory, anti-viral and pharmacological efficacy significantly inhibited apoptosis by decreasing IL-1 β , TNF- α and inducible NO synthase (iNOS) in rats with experimentally induced OA [150]. The effect of shikonin in this animal model of OA was accompanied not only by reduced caspase-3 and cyclooxygenase-2 activity but also by increased activation of Akt, indicating a prominent role for PI3K/Akt signaling in this rat model of OA. Finally, a few novel targets, including protein kinase R-like endoplasmic reticulum kinase and activating transcription factor 6, were identified as potent regulators of chondrocyte apoptosis *in vitro* and *in vivo* [151], although the precise signaling mechanisms attributed to these molecules have yet to be completely established.

5.2. Additional potential targets related to apoptosis

Several experimental studies, of note, have focused on several cellular components which may eventually become suitable pharmacologic targets for altering chondrocyte apoptosis and/or autophagy in osteoarthritis (Table 2). However, the results of these mainly *in vitro* studies point out why it will be necessary to determine the underlying mechanisms regarding how these factors work to inhibit apoptosis. Thus, only after successful evaluation in animal models of RA and OA, can we envision that these targets could eventually be employed in a clinical setting.

Factor	Target	Reference
HIF-1α/HIF-2α ¹	HIF-1α—SOX9; HIF-2α—Fas	[152]
Integrin-β1	G1T1 ²	[153]
IGFBP-3 ³	Nur77 ⁴	[154]
SGBT ⁵	Caspase-3/Hsp70 ⁶	[155]
UCP4 ⁷	ROS ⁸	[156]
DEL1 ⁹	Caspase-3/Caspase-7	[157]
Rela ¹⁰	Pik3r1 ¹¹	[158]
Beclin ¹²	Bcl-2; Bcl-2 associated X	[159]
AST ¹³	LC3-II/I ¹⁴ ; P62/SQSTM1 ¹⁵	[160]
AQP-1 ¹⁶	Caspase-3	[161]
Mt1/Mt2 ¹⁷	ROS ⁸	[162]
Sirt1 ¹⁸	Bcl-2; Bax	[163]

¹Hypoxia-inducible factor-1α/-2α.
²G-protein-coupled receptor kinase interacting protein-1.
³Insulin-like growth factor-1 binding protein-3.
⁴Nerve growth factor 1B.
⁵Small glutamine-rich tetratricopeptide repeat-containing β.
⁶Heat shock protein-70.
⁷Uncoupling protein-4.
⁸Reactive oxygen species.
⁹Developmental endothelial locus-1.
¹⁰RelA/p65 of NF-κB complex.
¹¹Pik3r1 encodes a p85α regulatory protein that is a subunit of phosphatidylinositol 3-kinase (PI3K).
¹²Beclin-1, a product of the *BECN1* gene is a mammalian ortholog of the yeast autophagy-related gene 6 (Atg6) and BEC-1 in the *C. elegans* nematode.
¹³Astragaloside IV.
¹⁴Microtubule-associated protein 1A/1B-light chain-I/II.
¹⁵P62/sequestosome-1.
¹⁶Aquaporin-1.
¹⁷Metallothionein-1/metallothionein-2.
¹⁸Silent information regulation of transcription 1.

Table 2. Cellular factors that regulate chondrocyte apoptosis and/or autophagy *in vitro*.

6. Conclusions and future perspectives

It is now generally agreed upon by many investigators that a chronic state of inflammation is, in part, responsible for driving and perpetuating the progression of RA (reviewed in [94]) and OA (reviewed in [58, 164]). Moreover, additional recent evidence has indicated that both apoptosis and an altered state of autophagy are critical events in chronic musculoskeletal disorders, such as RA and OA [60, 102–105, 164–167]. Although the loss of chondrocyte vitality

is a common pathological finding in RA and OA, cellular mechanisms that result in synovial fibroblast and immune-cell-mediated “apoptosis-resistance,” such as those that were found to underlie B-cell activity in RA [168–171], aids in distinguishing between the fundamental underpinning responsible for bony abnormalities in the two conditions. However, equally important is that the increased frequency of apoptotic chondrocytes in both RA and OA constitutes a major contributor to inefficient cartilage repair and synovial joint failure. We contend that any pharmacologic strategies designed to simultaneously target the “apoptosis-resistance” in the RA hyperplastic synovial tissue and the elevated frequency of chondrocyte apoptosis would be an onerous undertaking. So for the present, concentrating on developing agents that suppress or inhibit chondrocyte apoptosis might be the initial way to proceed. For example, the current literature on this subject has already indicated that certain drugs used in the medical therapy of RA suppress chondrocyte apoptosis *in vitro*. In that regard, the drug sulphasalazine, commonly employed in combination with methotrexate, for treating RA [172] was found to inhibit rabbit chondrocyte apoptosis induced by SNP [173]. In this study, the reduced frequency of chondrocyte apoptosis was accompanied by an increase in phosphorylated p38 kinase and ERK1/2 expression compared to treatment of chondrocytes with SNP alone.

Another area worthy of consideration is to employ *in vitro* studies to, in effect, rule out for further considerations for developing drugs for treating potential targets of chondrocyte apoptosis. A suitable example of this strategy was a recent finding by Nasi et al. [174] that the NALP3 inflammasome (reviewed in [175]) was not involved in chondrocyte apoptosis characteristic of several alterations in cartilage characteristically found in a murine meniscectomy model of OA. Although alterations in the structure of articular cartilage such as cartilage destruction, synovial inflammation, cell death and calcification were seen in this OA animal model, a deficiency in IL-1 α had no impact on these features. Importantly, deficiencies in IL-1 β and NALP3 actually resulted in an enhancement of cartilage damage in this OA animal model.

The suppression or more favorably the complete inhibition of chondrocyte apoptosis in RA and OA using pharmacologic interventional strategies would be a laudable achievement in the continuing search for novel disease-modifying-anti-rheumatic drugs. A variety of potential novel targets have now been identified during the previous 3 years that at least employing cancer cells induces the frequency of apoptosis. Thus, targets have been identified to induce apoptosis in these cancers and therefore, may be eventually exploited for blocking chondrocyte apoptosis. For example, the activity of 2,5-dihydroxy-3-undecyl-1,4 benzoquinone, 6 g, also known as embelin was reviewed [82] as an inducer of apoptosis in inflammatory breast cancer cells and pancreatic cancer cells. Embelin was also shown to block the transcription of several gene products relevant to tumor cell survival, proliferation, invasiveness and metastatic cancer cell proliferation. Of note, treatment with non-toxic concentrations of embelin could also sensitize cultured malignant glioma to TRAIL-induced apoptosis [176]. Lewis and Malemud [82] reviewed the findings showing that embelin blocked the activation of NF- κ B, RANKL and, STAT3, the latter finding demonstrating “proof-of-principle” that STAT3-activated transcription could also be employed to probe the extent to which this signaling pathway was required for maintaining chondrocyte survival *in vitro* [177]. In that regard, these pre-clinical results may provide a suitable platform for exploiting the overall objective of preventing synovial joint failure in RA and OA through the maintenance of normal articular chondrocyte viability and cartilage integrity.

Acknowledgements

The results of experimental studies cited in Refs. [70, 72, 77, 80] were supported in part by grants from the National Institutes of Health, Takeda Pharmaceuticals of North America and Genentech/Roche Group.

Author details

Charles J. Malemud

Address all correspondence to: cjm4@cwru.edu

Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University School of Medicine/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA

References

- [1] Reed JC. Bcl-2 and the regulation of programmed cell death. *Journal of Cell Biology*. 1994;**124**:1-6. PMCID: PMC2119888
- [2] Ashkenazi A, Dixit M. Death receptors: Signaling and modulation. *Science*. 1998;**281**:1305-1308. PMID: 9721089
- [3] Opferman JT, Letia A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. *Nature*. 2003;**426**:671-676. DOI: 10.1038/nature02067
- [4] Schultz DR, Harrington WJ Jr. Apoptosis: Programmed cell death at a molecular level. *Seminars in Arthritis & Rheumatism*. 2003;**32**:345-369. DOI: 10.1053/sarh.2003.50005
- [5] Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. *Annual Review of Immunology*. 2003;**21**:139-176. DOI: 10.1146/annurev.immunol.21.120601.141107
- [6] Hernandez JB, Newton RH, Walsh CM. Life and death in the thymus—Cell death signaling during T cell development. *Current Opinion in Cell Biology*. 2010;**22**:865-871. DOI: 10.1016/j.ceb.2010.08.003
- [7] Malemud CJ. Immunotherapies and rheumatoid arthritis-introduction. *Journal of Clinical and Cellular Immunology*. 2013;**S6**:e001
- [8] Wolfer A, Wilson A, Nemir M, et al. Inactivation of Notch1 impairs VDJ β rearrangement and allows pre-TCR-independent survival of early $\alpha\beta$ lineage thymocytes. *Immunity*. 2002;**16**:869-879. PMID: 12121668
- [9] Schultzke JD, Bojarski C, Zeissig S, et al. Disrupted barrier function through epithelial cell apoptosis. *Annals of the New York Academy of Sciences*. 2006;**1072**:288-299. DOI: 10.1196/annals.1326.027

- [10] Beug ST, Cheung HH, LaCasse EC, et al. Modulation of immune signaling by inhibitors of apoptosis. *Trends in Immunology*. 2012;**33**:535-545. DOI: 10.1016/j.it.2012.06.004
- [11] Liu H, Pope RM. Apoptosis in rheumatoid arthritis: Friend or foe. *Rheumatic Disease Clinics of North America*. 2004;**30**:603-625. DOI: 10.1016/j.rdc.2004.04.010
- [12] Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. *Current Rheumatology Reviews*. 2005;**1**:131-142
- [13] Korb A, Pavenstädt H, Pap T. Cell death in rheumatoid arthritis. *Apoptosis*. 2009;**14**:447-454. DOI: 10.1007/s10495-009-0317-y
- [14] Kim HA, Blanco FJ. Cell death and apoptosis in osteoarthritis. *Current Drug Targets*. 2007;**8**:333-345. PMID: 17305511
- [15] Del Carlo M Jr, Loesser RF. Cell death in osteoarthritis. *Current Rheumatology Reports*. 2008;**10**:37-42. PMID: 18457610
- [16] Zamli Z, Sharif M. Chondrocyte apoptosis: A cause or consequence of osteoarthritis. *International Journal of Rheumatic Diseases*. 2011;**14**:159-166. DOI: 10.1111/j.1756-185X.2011.01618.x
- [17] Cope AP, Schultze-Koops H, Aringer AM. The central role of T cells in rheumatoid arthritis. *Clinical and Experimental Rheumatology*. 2007;**5**(Suppl 46):S4-S11. PMID: 17977483
- [18] Hutcheson J, Perlman H. Apoptotic regulators and RA. *Current Rheumatology Reviews*. 2008;**4**:254-258
- [19] Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. *Open Access Rheumatology: Research and Reviews*. 2009;**1**:133-150. PMID: 27789987
- [20] Charlier E, Relic B, Deroyer C, et al. Insights on the mechanisms of chondrocyte death in osteoarthritis. *International Journal of Molecular Sciences*. 2016;**17**. pii. E2146. DOI: 10.3390.ijms17122146
- [21] Wu L, Liu Z. The molecular mechanisms of preventing apoptosis of cartilage chondrocyte to target osteoarthritis. *Future Medicinal Chemistry*. 2017;**9**:537-540. DOI: 10.4155/fmc-2017-0034
- [22] Kühn K, Shikhman AR, Lotz M. Role of nitric acid, reactive oxygen species, and 38 MAP kinase in the regulation of human chondrocyte apoptosis. *Journal of Cellular Physiology*. 2003;**197**:379-387. DOI: 10.1002/jcp.10372
- [23] Deng Y, Ren X, Yang L, et al. A JNK-dependent pathway is required for TNF- α -induced apoptosis. *Cell*. 2003;**115**:61-70 14532003
- [24] Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. *Current Opinion in Rheumatology*. 2007;**19**:246-251. DOI: 10.1097/BOR.0b013e3280eed78c
- [25] Wisler BA, Dennis JE, Malemud CJ. New organ-specific pharmacological strategies interfering with signal pathways in inflammatory disorders/autoimmune disorders. *Current Signal Transduction Therapy*. 2011;**6**:279-291

- [26] Ivashkiv LB, Xu X. Signaling by STATs. *Arthritis Research & Therapy*. 2004;**6**:159-168. DOI: 10.1186/ar1197
- [27] Kaplan MH. STAT4: A critical regulator of inflammation *in vivo*. *Immunologic Research*. 2005;**31**:231-242. DOI: 10.1385/IR:31:3:231
- [28] Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory diseases. *Current Signal Transduction Therapy*. 2009;**4**:201-221
- [29] Stark GR, Darnell JE Jr. The JAK-STAT pathway at 20. *Immunity*. 2012;**36**:503-514. DOI: 10.1016/j.immuni.2012.03.013
- [30] Rani A, Murphy JJ. STAT5 in cancer and immunity. *Journal of Interferon Cytokine Research*. 2016;**36**:226-237. DOI: 10.1089/jir.2015.0054
- [31] Malemud CJ. Negative regulators of JAK/STAT signaling in rheumatoid arthritis and osteoarthritis. *International Journal of Molecular Sciences*. 2017;**18**. pii: E484. DOI: 10.3390/ijms18030484
- [32] Choy E. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. *Rheumatology (Oxford, England)*. 2012;**51**(Suppl 5):v3-v11. DOI: 10.1093/rheumatology/kes113
- [33] Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. *Open Rheumatology*. 2012;**6**:245-258. DOI: 10.2174/1874312901206010245
- [34] Nagai S, Kurebayashi Y, Koyasu S. Role of PI3K/Akt and mTOR complexes in Th17 differentiation. *Annals of the New York Academy of Sciences*. 2013;**1280**:30-34. DOI: 10.1111/nyas.12059
- [35] Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: Progress and promises. *Autoimmunity*. 2014;**47**:77-94. DOI: 10.3109/08916934.2013.873413
- [36] Malemud CJ. The PI3K/Akt/PTEN/mTOR pathway: A fruitful target for inducing cell death in rheumatoid arthritis? *Future Medicinal Chemistry*. 2015;**7**:1137-1147. DOI: 10.4155/fmc.15.55
- [37] Tristano AG. Tyrosine kinases as targets in rheumatoid arthritis. *International Immunopharmacology*. 2009;**9**:1-9. DOI: 10.1016/j.intimp.2008.09.010
- [38] Malemud CJ. The discovery of novel experimental therapies for inflammatory arthritis. *Mediators of Inflammation*. 2009;**2009**:698769. DOI: 10.1155/2009/698769
- [39] Tan SL, Liao C, Lucas MC, et al. Targeting the SyK-BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives. *Pharmacologic Therapy*. 2013;**138**:294-309. DOI: 10.1016/j.pharmthera.2013.02.001
- [40] Malemud CJ. Investigative drugs for rheumatoid arthritis: Novel targets. *Journal of Autoimmune Disorders*. 2016;**2**:12

- [41] Wu L, Huang X, Li L, et al. Insights on the biology and pathology of HIF-1 α /-2 α , TGF β /BMP, Wnt/ β -catenin, and NF- κ B pathways in osteoarthritis. *Current Pharmaceutical Design*. 2012;**18**:3293-3312. PMID: 22646092
- [42] Husa M, Petursson F, Lotz M, et al. C/EBP homologous protein drives pro-catabolic responses in chondrocytes. *Arthritis Research & Therapy*. 2013;**15**:R218. DOI: 10.1186/ar4415
- [43] Wang X, Xu Z, Wang J, et al. DUSP19, a downstream effector of leptin, inhibits chondrocyte apoptosis via dephosphorylating JNK during osteoarthritis pathogenesis. *Molecular BioSystems*. 2016;**12**:721-728. DOI: 10.1039/c5mb00776c
- [44] Huang Y, Huang Q, Su H, et al. TAR DNA-binding protein 43 inhibits inflammatory responses and protects chondrocyte function by modulating RACK1 expression in osteoarthritis. *Biomedicine & Pharmacotherapy*. 2017;**85**:362-371. DOI: 10.1016/j.biopha.2016.11.037
- [45] Yu C, Chen WP, Wang XH. MicroRNA and osteoarthritis. *Journal of International Medical Research*. 2011;**39**:1-9. DOI: 10.1177/147323001103900101
- [46] Diaz-Prado S, Cicione C, Mulños-López E, et al. Characterization of microRNA expression in normal and osteoarthritic human chondrocytes. *BMC Musculoskeletal Disorders*. 2012;**13**:144. DOI: 10.1186/1471-2474-13-144
- [47] Genemaras AA, Ennis H, Kaplan L. Inflammatory cytokines induce specific time- and concentration-dependent MicroRNA release by chondrocytes, synoviocytes and meniscus cells. *Journal of Orthopaedic Research*. 2016;**34**:779-790. DOI: 10.1002/jor.23086
- [48] Cong L, Zhu Y, Tu G. A bioinformatics analysis of microRNAs in osteoarthritis. *Osteoarthritis and Cartilage*. 2017;**25**:1362-1371. DOI: 10.1016/j.joca.2017.03.012
- [49] Zamli Z, Adams MA, Tarlton JF, et al. Increased chondrocyte apoptosis is associated with the progression of osteoarthritis in spontaneous Guinea pig models of the disease. *International Journal of Molecular Sciences*. 2013;**14**:17729-17743. DOI: 10.3390/ijms140917729
- [50] Karouzakis E, Neidhart M, Gay RE, et al. Molecular and cellular basis of rheumatoid joint destruction. *Immunology Letters*. 2006;**106**:8-13. DOI: 10.1016/j.imlet.2006.04.011
- [51] Huber LC, Distler O, Tarner I, et al. Synovial fibroblasts: Key player in rheumatoid arthritis. *Rheumatology (Oxford, England)*. 2006;**45**:669-675. DOI: 10.1093/rheumatology/kel065
- [52] Johnson EQ, Charchandi A, Babis GC, et al. Apoptosis in osteoarthritis: Morphology, mechanisms, and potential means for therapeutic intervention. *Journal of Surgery Orthopedic Advances*. 2008;**17**:147-152. PMID: 18851798
- [53] Thomas CM, Fuller CJ, Whittles CE, et al. Chondrocyte death by apoptosis is associated with the initiation and severity of articular cartilage degradation. *International Journal of Rheumatic Diseases*. 2011;**14**:191-198. DOI: 10.1111/j.1756-185X.2010.01578.x

- [54] Dowthwaite GP, Bishop JC, Redman SN, et al. The surface of articular cartilage contains a progenitor cell population. *Journal of Cell Science*. 2004;**117**:889-897. DOI: 10.1242/jcs.00912
- [55] Alsalameh S, Amin R, Gemba T, et al. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. *Arthritis and Rheumatism*. 2004;**50**:1522-1532. DOI: 10.1002/art.20269
- [56] Koeling S, Kruegel J, Imer M, et al. Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. *Cell Stem Cell*. 2009;**4**:324-335. DOI: 10.1016/j.stem.2009.01.015
- [57] Schimke B, Trautman S, Mai B, et al. Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage. *European Journal of Immunology*. 2016;**46**:440-445. DOI: 10.1002/eji.201545910
- [58] Malesud CJ. Apoptosis resistance in rheumatoid arthritis synovial tissue. *Journal of Clinical and Cellular Immunology*. 2011;**S3**:006
- [59] Malesud CJ, Mobasher A, editors. *International Journal of Medical Sciences*. Special Issue: Apoptotic Chondrocytes and Osteoarthritis
- [60] Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. *Nature Reviews. Rheumatology*. 2015;**11**:35-44. DOI: 10.1038/nrrheum.2014.162
- [61] Malesud CJ. Biologic basis of osteoarthritis: State of the evidence. *Current Opinion in Rheumatology*. 2015;**27**:289-294. DOI: 10.1097/BOR.0000000000000162
- [62] Miossec P. An update on the cytokine network in rheumatoid arthritis. *Current Opinion in Rheumatology*. 2004;**16**:218-222. DOI: 10.1097/BOR.0000000000000162
- [63] Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. *Current Opinion in Rheumatology*. 2007;**19**:296-301. DOI: 10.1097/BOR.0b013e32805e87f1
- [64] Malesud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. *Current Rheumatology Reviews*. 2008;**4**:219-234
- [65] Houard X, Goldring MB, Berenbaum F. Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis. *Current Rheumatology Reports*. 2013;**15**:375. DOI: 10.1007/s11926-013-0375-6
- [66] Malesud CJ. Growth hormone, VEGF and FGF: Involvement in rheumatoid arthritis. *Clinica Chimica Acta*. 2007;**375**:10-19. DOI: 10.1016/j.cca.2006.06.033
- [67] Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF- α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. *Osteoarthritis and Cartilage*. 2010;**18**:1441-1447. DOI: 10.1016/j.joca.2010.08.016
- [68] Abe H, Sakai T, Ando W, et al. Synovial fluid cytokine levels in hip disease. *Rheumatology (Oxford, England)*. 2014;**53**:165-172. DOI: 10.1093/rheumatology/ket334

- [69] Zan PF, Yao J, Wu Z, et al. Cyclin D1 gene silencing promotes IL-1 β -induced apoptosis in rat chondrocytes. *Journal of Cellular Biochemistry*. 2018;**119**:290-299. DOI: 10.1002/jcb.26172
- [70] Islam N, Haqqi TM, Jepsen KJ, et al. Hydrostatic pressure induces apoptosis in human chondrocytes from osteoarthritic cartilage through up-regulation of tumor necrosis factor- α , inducible nitric oxide synthase, p53, c-myc and bax- α and suppression of bcl-2. *Journal of Cellular Biochemistry*. 2002;**87**:266-278. DOI: 10.1002/jcb.10317
- [71] Caramés B, López-Armada MJ, Cillero-Pastor B, et al. Differential effects of tumor necrosis factor- α and interleukin-1- β on cell death in human articular chondrocytes. *Osteoarthritis and Cartilage*. 2008;**16**:715-722. DOI: 10.1016/j.joca.2007.10.006
- [72] Malesmud CJ, Sun Y, Pearlman E, et al. Monosodium urate and tumor necrosis factor- α increase apoptosis in human chondrocyte cultures. *Rheumatology (Sunnyvale)*. 2012;**2**:113. DOI: 10.4172/2161-1149.1000113
- [73] Wang Y, Li de L, Zhang XB, et al. Increase of TNF α -stimulated osteoarthritic chondrocytes apoptosis and decrease of matrix metalloproteinase-9 by NF- κ B inhibition. *Biomedical and Environmental Sciences*. 2013;**26**:277-283. DOI: 10.3967/0895-3988.2013.04.006
- [74] Cheleschi S, Cantarini L, Pascarelli NA, et al. Possible chondroprotective of canakinumab: An in vitro study of human osteoarthritic chondrocytes. *Cytokine*. 2015;**71**:165-172. DOI: 10.1016/j.cyto.2014.10.023
- [75] Lu H, Zeng C, Chen M, et al. Lentiviral vector-mediated over-expression of Sox9 protected chondrocytes from IL-1 β induced degeneration and apoptosis. *International Journal of Clinical and Experimental Pathology*. 2015;**8**:10038-10049. PMCID: PMC4637526
- [76] Shi X, Ye H, Yao X, et al. The involvement and possible mechanism of NR4A1 in chondrocyte apoptosis during osteoarthritis. *American Journal of Translational Research*. 2017;**9**:746-754. PMCID: PMC5340710
- [77] Malesmud CJ, Lewis AC, Wylie MA, et al. U0126, an inhibitor of MEK1/2, increases tumor necrosis factor- α -induced apoptosis, but not interleukin-6-induced apoptosis in C-28/I2 human chondrocytes. *Journal of Autoimmune Disorders*. 2015;**1**:4. PMCID: PMC4739803
- [78] Malesmud CJ. Anticytokine therapy for osteoarthritis. Evidence to date. *Drugs & Aging*. 2010;**27**:95-115. DOI: 10.2165/11319950-000000000-00000
- [79] Malesmud CJ. Suppression of pro-inflammatory cytokines via targeting of STAT-responsive genes. In: El-Shemy H, editor. *Drug Discovery*. Rijeka: InTech Publishing; 2013. pp. 373-411
- [80] Meszaros EC, Malesmud CJ. Phosphorylation of STAT proteins by recombinant human IL-6 in immortalized human chondrocyte cell lines, T/C28a2 and C28/I2. *Journal of Inflammation Research*. 2017;**10**:1-8. DOI: 10.2147/JIR.593797
- [81] Arora V, Cheung HH, Plenchette S, et al. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. *The Journal of Biological Chemistry*. 2007;**282**:26202-26209. DOI: 10.1074/jbc.M700776200

- [82] Lewis AC, Malemud CJ. Correction of dysfunctional apoptosis in arthritis by pharmacologic interventions: Focus on altering the activity of inhibitor of apoptosis protein. In: Pandalai SG, editor. *Recent Research Developments in Pharmacology*. Kerala: Research Signpost; 2011. pp. 69-84
- [83] Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological disorders. *Current Molecular Medicine*. 2011;**11**:633-649. PMID: 21902653
- [84] Saleem M, Qadir MI, Perveen N, et al. Inhibitors of apoptosis proteins: New targets for anticancer therapy. *Chemical Biology & Drug Design*. 2013;**82**:243-251. DOI: 10.1111/cbdd.12176
- [85] Malemud CJ. Suppressor of cytokine signaling and rheumatoid arthritis. *Integrative Molecular Medicine*. 2016;**3**:17-20
- [86] He Q, Sun C, Lei W, et al. SOCS1 regulates apoptosis and inflammation by inhibiting IL-4 signaling in IL-1 β -stimulated human osteoarthritic chondrocytes. *BioMed Research International*. 2017;**2017**:4601959. DOI: 10.1055/2017/4601959
- [87] Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. *Nature Reviews Rheumatology*. 2011;**7**:161-169. DOI: 10.1038/nrrheum.2010.213
- [88] Takada K, Hirose J, Yamabe S, et al. Endoplasmic reticulum stress mediates nitric-oxide-induced chondrocyte apoptosis. *Biomedical Reports*. 2013;**1**:315-319. DOI: 10.3892/br.2013.52
- [89] Uehara Y, Hirose J, Yamabe S, et al. Endoplasmic reticulum-stress-induced apoptosis contributes to articular cartilage degeneration via C/EBP homologous protein. *Osteoarthritis and Cartilage*. 2014;**22**:1007-1017. DOI: 10.1016/j.joca.2014.04.025
- [90] Hughes A, Oxford AE, Tawara K, et al. Endoplasmic reticulum stress and unfolded protein response in cartilage pathophysiology: Contributing factors to apoptosis and osteoarthritis. *International Journal of Molecular Sciences*. 2017;**18**. pii: E665. DOI: 10.3390/ijms18030665
- [91] Li XF, Zhang Z, Chen ZK, et al. Piezo protein induces the apoptosis of human osteoarthritis-derived chondrocytes by activating caspase-12, the signaling marker of ER stress. *International Journal of Molecular Medicine*. 2017;**40**:845-853. DOI: 10.3892/ijmm.2017.3075
- [92] Li D, Xie G, Wang W. Reactive oxygen species: The 2-edged sword of osteoarthritis. *The American Journal of Medical Sciences*. 2012;**344**:486-490. DOI: 10.1097/MAJ.0b013e3182579dc6
- [93] Wu Q, Zhong ZM, Zhu SY, et al. Advanced oxidation protein products induce chondrocyte apoptosis via receptor for advanced glycation end products-mediated, redox-dependent intrinsic apoptosis pathway. *Apoptosis*. 2016;**21**:36-50. DOI: 10.1007/s10495-015-1191-4
- [94] Angelotti F, Parma A, Cafaro G, et al. One year in review 2017: Pathogenesis of rheumatoid arthritis. *Clinical and Experimental Rheumatology*. 2017;**35**:368-378. PMID: 28631608

- [95] Battistelli M, Salucci S, Olivotto E, et al. Cell death in human articular chondrocytes. A morpho-functional study in micromass model. *Apoptosis*. 2014;**19**:1471-1483. DOI: 10.1007/s10495-014-1017-9
- [96] Gu YY, Chen J, Meng ZL, et al. Research progress on osteoarthritis mechanisms. *Biomedical Pharmacotherapy*. 2017;**93**:1246-1252. DOI: 10.1016/j.biopha.2017.07.034
- [97] Hwang HS, Kim HA. Chondrocyte apoptosis in the pathogenesis of osteoarthritis. *International Journal of Molecular Sciences*. 2015;**16**:26035-26054. DOI: 10.3390/ijms161125943
- [98] Roach HI, Aigner T, Kouri JB. Chondropotosis: A variant of apoptotic cell death in osteoarthritis. *Apoptosis*. 2004;**9**:265-277 15258458
- [99] Lin NY, Beyer C, Giessel A, et al. Autophagy regulates TNF α -mediated joint destruction in experimental arthritis. *Annals of the Rheumatic Diseases*. 2013;**72**:761-768. DOI: 10.1136/annrheumdis-2012-201671
- [100] Dai Y, Hu S. Recent insights into the role of autophagy in the pathogenesis of rheumatoid arthritis. *Rheumatology (Oxford, England)*. 2016;**55**:403-410. DOI: 10.1093/rheumatology/kev337
- [101] Speziali A, Delcogliano M, Tei M, et al. Chondropenia: Current concept review. *Musculoskeletal Surgery*. 2015;**99**:189-200. DOI: 10.1007/s12306-015-0377-9
- [102] Chang J, Wang W, Zhang H, et al. The dual role of autophagy in chondrocyte responses in the pathogenesis of articular cartilage degeneration in osteoarthritis. *International Journal of Molecular Medicine*. 2013;**32**:1311-1318. DOI: 10.3892/ijmm.2013.1520
- [103] Musumeci G, Castrogiovanni P, Trovato FM, et al. Biomarkers of chondrocyte apoptosis and autophagy in osteoarthritis. *International Journal of Molecular Sciences*. 2015;**16**:20560-20575. DOI: 10.3390/ijms160920560
- [104] Jeon H, Im GI. Autophagy in osteoarthritis. *Connective Tissue Research*. 2017;**58**:497-508. DOI: 10.1080/03008207.2016.1240790
- [105] Li YS, Zhang FJ, Zeng C, et al. Autophagy in osteoarthritis. *Joint, Bone, Spine*. 2016;**83**:143-148. DOI: 10.1016/j.jbspin.2015.06.009
- [106] Wylie MA, Malesud CJ. Perspective: Deregulation of apoptosis in arthritis by altered signal transduction. *International Journal of Clinical Rheumatology*. 2013;**8**:483-490. DOI: 10.2217/IJR.13.31
- [107] Musumeci G, Loreto C, Carnazza M, et al. Characterization of apoptosis in articular cartilage derived from the knee joints of patients with osteoarthritis. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2011;**19**:307-313. DOI: 10.1007/s00167-010-1215-0
- [108] Huang ZM, Du SH, Huang LG, et al. Leptin promotes apoptosis and inhibits autophagy of chondrocytes through upregulating lysyl oxidase-like 3 during osteoarthritis pathogenesis. *Osteoarthritis and Cartilage*. 2016;**24**:1246-1253. DOI: 10.1016/j.joca.2016.02.009

- [109] Zhang Y, Vasheghani F, Li YH, et al. Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. *Annals of Rheumatic Diseases*. 2015;**74**:1432-1440. DOI: 10.1136/annrheumdis-2013-204599
- [110] Shen C, Cai GQ, Peng JP, et al. Autophagy protects chondrocytes from glucocorticoid-induced apoptosis via ROS/Akt/FOXO3 signaling. *Osteoarthritis and Cartilage*. 2015;**23**:2279-2287. DOI: 10.1016/j.joca.2015.06.020
- [111] Huang W, Ao P, Li J, et al. Autophagy protects advanced glycation end product-induced apoptosis and expression of MMP-3 and MMP-13 in rat chondrocytes. *Biomedical Research International*. 2017;**2017**:6341919. DOI: 10.1155/2017/6341919
- [112] Sera SR, Zur Nieden NI. microRNA regulation of skeletal development. *Current Osteoporosis Reports*. 2017;**15**:353-366. DOI: 10.1007/s11914-017-0379-7
- [113] Churov AV, Oleinik EK, Knip M. MicroRNAs in rheumatoid arthritis: Altered expression and diagnostic potential. *Autoimmune Reviews*. 2015;**14**:1029-1037. DOI: 10.1016/j.autrev.2015.07.005
- [114] Haftmann C, Stittrich AB, Zimmermann J, et al. miR-148a is upregulated by Twist1 and t-bet and promotes Th1-survival by regulating the proapoptotic gene Bim. *European Journal of Immunology*. 2015;**45**:1192-1205. DOI: 10.1002/eji.201444633
- [115] D'Adamo S, Cetrullo S, Minguzzi M, et al. MicroRNAs and autophagy: Fine players in the control of chondrocyte homeostatic activities in osteoarthritis. *Oxidative Medicine and Cellular Longevity*. 2017;**2017**:3720128. DOI: 10.1155/2017/3720128
- [116] Malesmud CJ. Chondrocyte apoptosis in rheumatoid arthritis: Is preventive therapy possible? *Immunotherapy (Los Angel)*. 2015;**1**. pii: 102. PMID: 26878072
- [117] Jin L, Zhao J, Jing W, et al. Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro. *International Journal of Molecular Medicine*. 2014;**34**:451-463. DOI: 10.3892/ijmm.2014.1808
- [118] Zhong JH, Li J, Liu CF, et al. Effects of microRNA-146a on the proliferation and apoptosis of human osteoarthritis chondrocytes by targeting TRAF6 through the NF- κ B signaling pathway. *BioScience Reports*. 2017;**37**. pii: BSR20160578. DOI: 10.1042/BSR20160578
- [119] West C, McDermott MF. Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κ B signalling pathway. *BioScience Reports*. 2017;**37**:BSR20170180. DOI: 10.1042/BSR20170180
- [120] Li J, Huang J, Dai L, et al. miR-146a, an IL-1 β responsive miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4. *Arthritis Research & Therapy*. 2012;**14**:R75. DOI: 10.1187/ar3798
- [121] Abouheif MM, Nakasa T, Shibuya H, et al. Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro. *Rheumatology (Oxford, England)*. 2010;**49**:2054-2060. DOI: 10.1093/rheumatology/keg247

- [122] Yan S, Wang M, Zhao J, et al. Micro-RNA-34a affects chondrocyte apoptosis and proliferation by targeting the SIRT1/p53 signaling pathway during the pathogenesis of osteoarthritis. *International Journal of Molecular Medicine*. 2016;**38**:201-209. DOI: 10.3892/ijmm.2016.2618
- [123] Chen H, Wang J, Hu B, et al. MiR-34a promotes Fas-mediated cartilage endplate chondrocyte apoptosis by targeting Bcl-2. *Molecular and Cellular Biochemistry*. 2015;**406**:21-30. DOI: 10.1007/s11010-015-2420-4
- [124] Zhai X, Meng R, Li H, et al. miR-181a modulates chondrocyte apoptosis by targeting glycerol-3-phosphate dehydrogenase 1-like protein (GPD1L) in osteoarthritis. *Medical Science Monitor*. 2017;**23**:1224-1231. PMCID: PMC5360418
- [125] Wu XF, Zhou ZH, Zou J. MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN. *Biochemistry and Cell Biology*. 2017;**95**:437-444. DOI: 10.1139/bcb-2016-0078
- [126] Malesmud CJ. Matrix metalloproteases and synovial joint pathology. In: Khalil RA, editor. *Progress in Molecular Biology and Translational Science*. Vol. 148. Burlington: Academic Press; 2017. pp. 306-325
- [127] Wang GL, Wu YB, Liu JT, et al. Upregulation of miR-98 inhibits apoptosis in cartilage cells in osteoarthritis. *Genetic Testing and Molecular Biomarkers*. 2016;**20**:645-653. DOI: 10.1089/gtmb/2016.0011
- [128] Wang J, Chen L, Jin S, et al. MiR-98 promotes chondrocyte apoptosis by decreasing Bcl-2 expression in a rat model of osteoarthritis. *Acta Biochimica Biophysica Sin (Shanghai)*. 2016;**48**:923-929. DOI: 10.1093/abbs/gmw084
- [129] Wang J, Chen L, Jin S, et al. Altered expression of microRNA-98 in IL-1 β -induced cartilage degradation and its role in chondrocyte apoptosis. *Molecular Medicine Reports*. 2017;**16**:3208-3216. DOI: 10.3892/mmr.2017.7028
- [130] Song J, Kim D, Chun CH, et al. MicroRNA-9 regulates survival of chondroblasts and cartilage integrity by targeting protogenin. *Cell Communication and Signaling*. 2013; **11**:66. DOI: 10.1186/1478-811X-11-66
- [131] Chen H, Tian Y. MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA. *Bioscience Trends*. 2017;**10**:482-488. DOI: 10.5582/bst.2016.01187
- [132] Wang X, Guo Y, Wang C, et al. MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. *Inflammation*. 2016;**39**:1718-1728. DOI: 10.1007/s10753-016-0406-3
- [133] Zhang G, Sun Y, Wang Y, et al. MiR-502-5p inhibits IL-1 β -induced chondrocyte injury by targeting TRAF2. *Cellular Immunology*. 2016;**302**:50-57. DOI: 10.1016/j.cellimm.2016.01.007

- [134] Bai R, Zhao AQ, Zhao ZQ, et al. MicroRNA-195 induced apoptosis in hypoxic chondrocytes by targeting hypoxia-inducible factor 1 alpha. *European Review for Medical and Pharmacological Sciences*. 2015;**19**:545-551. PMID: 25753868
- [135] Makki MS, Haqqi TM. miR-139 modulates MCP1P1/IL-6 expression and induces apoptosis in human chondrocytes. *Experimental & Molecular Medicine*. 2015;**47**:e189. DOI: 10.1038/emm.2015.66
- [136] Chen L, Li Q, Wang J, et al. MiR-29b-3p promotes chondrocyte apoptosis and facilitates the occurrence and development of osteoarthritis by targeting PRGN. *Journal of Cellular and Molecular Medicine*. 2017;**21**:3347-3359. DOI: 10.1111/jcmm.13237
- [137] Li Y, Li S, Luo Y, et al. LncRNA PVT1 regulates chondrocyte apoptosis in osteoarthritis by acting as a sponge for miR-488-3p. *DNA Cell Biology*. 2017;**36**:571-580. DOI: 10.1089/dna.2017.3678
- [138] Zhao C, Wang Y, Jin H, et al. Knockdown of microRNA-203 alleviates LPS-induced injury by targeting MCL-1 in C28/I2 chondrocytes. *Experimental Cell Research*. 2017;**359**:171-178. DOI: 10.1016/j.yexcr.2017.07.034
- [139] Winsauer G, Resch U, Hofer-Warbinek R, et al. XIAP regulates bi-phasic NF- κ B induction involving physical interaction and ubiquitination of MEKK2. *Cell Signaling*. 2008;**11**:2107-2112. DOI: 10.1016/j.cellsig.2008.08.004
- [140] Rajalingam K, Dikic I. Inhibitors of apoptosis catch ubiquitin. *Biochemical Journal*. 2009;**417**:e1-e3. DOI: 10.1042/BJ20082215
- [141] Chen Q, Gao Y, Kao X, et al. SNP-induced apoptosis may be mediated with caspase inhibitor by JNK signaling pathways in rabbit articular chondrocytes. *The Journal of Toxicological Sciences*. 2012;**37**:157-167. PMID: 22293420
- [142] Ye Z, Chen Y, Zhang R, et al. C-Jun N-terminal kinase—C-Jun pathway transactivates Bim to promote osteoarthritis. *Canadian Journal of Physiology and Pharmacology*. 2014;**92**:132-139. DOI: 10.1139/cjpp-2013-0228
- [143] Xu L, Zhai L, Ge Q, et al. Vacuolar protein sorting 4B (VPS4B) regulates apoptosis of chondrocytes via p38 mitogen-activated protein kinases (MAPK) in osteoarthritis. *Inflammation*. DOI: 10.1007/s10753-017-0633-2
- [144] Sun HY, Hu KZ, Yin ZS. Inhibition of p38-MAPK signaling pathway suppresses the apoptosis and expression of proinflammatory cytokines in human osteoarthritis chondrocytes. *Cytokine*. 2017;**90**:135-143. DOI: 10.1016/j.cyto.2016.11.002
- [145] Shi J, Zhang C, Yi Z, et al. Explore the variation of MMP3, JNK, p38 MAPKs, and autophagy at the early stages of osteoarthritis. *IUBMB*. 2016;**68**:293-302. DOI: 10.1002/jub.1482
- [146] Zhang ZM, Shen C, Li H, et al. Leptin induces the apoptosis of chondrocytes in an in vitro model of osteoarthritis via the JAK2-STAT3 signaling pathway. *Molecular Medicine Reports*. 2016;**13**:3684-3690. DOI: 10.3892/mmr.2016.4970

- [147] Li D, Wu Z, Duan Y, et al. TNF α -mediated apoptosis in human osteoarthritic chondrocytes sensitized by PI3K-NF κ B inhibitor, not mTOR inhibitor. *Rheumatology International*. 2012;**32**:2017-2022. DOI: 10.1007/s00296-011-1929-4
- [148] Yin MH, Wang YT, Li Q, et al. Oligomeric proanthocyanidins inhibit apoptosis of chondrocytes induced by interleukin-1 β . *Molecular Medicine Reports*. . DOI: 10.3892/mmr.2017.7124
- [149] Rao Z, Wang S, Wang J. Peroxiredoxin 4 inhibits IL-1 β -induced chondrocyte apoptosis via PI3K/AKT signaling. *Biomedicine & Pharmacotherapy*. 2017;**90**:414-420. DOI: 10.1016/j.biopha.2017.03.075
- [150] Fu D, Shang X, Ni Z, et al. Shikonin inhibits inflammation and chondrocyte apoptosis by regulation of the PI3K/Akt signaling pathway in a rat model of osteoarthritis. *Experimental and Therapeutic Medicine*. 2016;**12**:2735-2740. DOI: 10.3892/etm.2016.3642
- [151] Wu Z, Li M, Zheng W, et al. Silencing of both ATF4 and PERK inhibits cell cycle progression and promotes the apoptosis of differentiating chondrocytes. *International Journal of Molecular Medicine*. 2017;**40**:101-111. DOI: 10.3892/ijmm.2017.2985
- [152] Zhang FJ, Luo W, Lei GH. Role of HIF-1 α and HIF-2 α in osteoarthritis. *Joint, Bone, Spine*. 2015;**82**:144-147. DOI: 10.1016/j.jbspin.2014.10.003
- [153] Zhang LO, Zhao GZ, Xu XY, et al. Integrin- β 1 regulates chondrocyte proliferation and apoptosis through the upregulation of G1T1 expression. *International Journal of Molecular Medicine*. 2015;**35**:1074-1080. DOI: 10.3892/ijmm.2015.2114
- [154] Wei Z, Li HH. IGFBP-1 may trigger osteoarthritis by inducing apoptosis of chondrocytes through Nur77 translocation. *International Journal of Clinical and Experimental Pathology*. 2015;**8**:15599-15610. PMCID: PMC4730042
- [155] Bao G, Xu L, Xu X, et al. SGBT promotes the caspase-dependent apoptosis in chondrocytes of osteoarthritis. *Inflammation*. 2016;**39**:601-610. DOI: 10.1007/s10753-015-0285-z
- [156] Huang Z, Li J, Du S, et al. Effects of UCP4 on the proliferation and apoptosis of chondrocytes: Its possible involvement and regulation in osteoarthritis. *PLoS One*. 2016;**11**:e0150684. DOI: 10.1371/journal.pone.0150684
- [157] Wang Z, Tran C, Bhatia NJ, et al. Del1 knockout mice developed more severe osteoarthritis associated with increased susceptibility of chondrocytes to apoptosis. *PLoS One*. 2016;**11**:e0160684. DOI: 10.1371/journal.pone.0160684
- [158] Kobayashi H, Chang SH, Mori D, et al. Biphasic regulation of chondrocytes by Rela through induction of anti-apoptotic and catabolic target genes. *Nature Communications*. 2016;**7**:13336. DOI: 10.1038/ncomms13336
- [159] Song B, Song H, Wang W, et al. Beclin 1 overexpression inhibits chondrocyte apoptosis and downregulates extracellular matrix metabolism in osteoarthritis. *Molecular Medicine Reports*. 2017;**16**:3958-3964. DOI: 10.3892/mmr.2017.7064

- [160] Liu J, Meng Q, Jing H, et al. Astragaloside IV protects against apoptosis in human degenerative chondrocytes through autophagy activation. *Molecular Medicine Reports*. 2017;**16**:3269-3275. DOI: 10.3892/mmr.2017.6980
- [161] Gao H, Gui J, Wang L, et al. Aquaporin 1 contributes to chondrocyte apoptosis in a rat model of osteoarthritis. *International Journal of Molecular Medicine*. 2016;**38**:1752-1758. DOI: 10.3892/ijmm.2016.2785
- [162] Won Y, Shin Y, Chun CH, et al. Pleiotropic roles of metallothioneins as regulators of chondrocyte apoptosis and catabolic and anabolic pathways during osteoarthritis pathogenesis. *Annals of the Rheumatic Diseases*. 2016;**75**:2045-2052. DOI: 10.1136/annrheumdis-2015-208406
- [163] He Ds HXJ, Yan YQ, et al. Underlying mechanism of Sirt1 on apoptosis and extracellular matrix degradation of osteoarthritis chondrocytes. *Molecular Medicine Reports*. 2017;**16**:845-850. DOI: 10.3892/mmr.2017.6659
- [164] Berenbaum F, Griffin TM, Liu-Bryan R. 2017; review: Metabolic regulation of inflammation in osteoarthritis. *Arthritis & Rheumatology*. 2017;**69**:9-21. DOI: 10.1002/art.39842
- [165] Sorice M, Iannuccelli C, Manganeli V, et al. Autophagy generates citrullinated peptides in human synoviocytes: A possible trigger for anti-citrullinated peptide antibodies. *Rheumatology (Oxford, England)*. 2016;**55**:1374-1385. DOI: 10.1093/rheumatology/kew178
- [166] Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. *Journal of Experimental Medicine*. 2011;**208**:2625-2632. DOI: 10.1084/jem.20110640
- [167] Van Loosdregt J, Rossetti M, Spreafico R, et al. Increased autophagy in CD4⁺ T cells of rheumatoid arthritis patients results in T-cell hyperactivation and apoptosis resistance. *European Journal of Immunology*. 2016;**46**:2862-2870. DOI: 10.1002/eji.201646375
- [168] Dalbeth N, Smith T, Gray S, Doyle A, Antill P, Lobo M, et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. *Annals of the Rheumatic Diseases*. 2009;**68**:279-282. DOI: 10.1136/ard.2008.096024
- [169] Yang J, Zhao S, Yang X, et al. Inhibition of B-cell apoptosis is mediated through increased expression of Bcl-2 in patients with rheumatoid arthritis. *International Journal of Rheumatic Diseases*. 2016;**19**:134-140. DOI: 10.1111/1756-185X.12706
- [170] Störch H, Zimmerman B, Resch B, et al. Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return. *Annals of the Rheumatic Diseases*. 2016;**75**:924-932. DOI: 10.1136/annrheumdis-2014-206965
- [171] Meednu N, Zhang H, Owen T, et al. Production of RANKL by memory B cells: A link between B cells and bone erosion and rheumatoid arthritis. *Arthritis & Rheumatology*. 2016;**68**:805-816. DOI: 10.1002/art.39489

- [172] Taherian E, Rao A, Malemud CJ, et al. The biological and clinical activity of anti-malarial drugs in autoimmune disorders. *Current Rheumatology Reviews*. 2013;**9**:45-62. PMID: 25198367
- [173] Lee WK, Kang JS. Modulation of apoptosis and differentiation by the treatment of sul-fasalazine in rabbit articular chondrocytes. *Toxicology Research*. 2016;**32**:115-121. DOI: 10.5487/TR.2016/32.2.115
- [174] Nasi S, Ea HK, So A, et al. Revisiting the role of interleukin-1 pathway in osteoarthritis: Interleukin-1 α and -1 β and NALP3 inflammasome are not involved in pathological features of the murine meniscectomy model of osteoarthritis. *Frontiers in Pharmacology*. 2017;**8**:282. DOI: 10.3389/fphar.2017.00282
- [175] Campbell L, Raheem I, Malemud CJ, et al. The relationship between NALP3 and auto-inflammatory syndromes. *International Journal of Molecular Sciences*. 2016;**17**:725. DOI: 10.3390/ijms17050725
- [176] Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. *Neurochemistry International*. 2009;**55**:423-430. DOI: 10.1016/j.neuint.2009.04.011
- [177] Malemud CJ. The small molecular weight inhibitor of protein kinase revolution for the treatment of rheumatoid arthritis. In: Vallisuta O, Olimat S, editors. *Drug Discovery and Development—From Molecules to Medicine*. Rijeka: InTech Publishing; 2015. p. 163-179. DOI: <http://dx.doi.org/10.5772/59639>

